Changeflow GovPing Pharma & Drug Safety EP4034086A1 Pharmaceutical Formulation Patent
Routine Rule Added Final

EP4034086A1 Pharmaceutical Formulation Patent

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office published application EP4034086A1 on April 8, 2026, filed by Hewlett Healthcare Limited, covering pharmaceutical formulations with IPC classifications including A61K 9/107, A61K 31/352, A61K 31/465, A61K 31/4741, A61K 45/06, A61P 17/00, A61P 17/10, A61P 19/02, A61K 9/00, and A61K 47/10. The patent designates 30+ European member states including DE, FR, GB, IT, NL, ES, and others. Inventor is Nigel Cooper.

What changed

The European Patent Office published patent application EP4034086A1 for Hewlett Healthcare Limited on April 8, 2026. The application covers pharmaceutical formulations including emulsions (A61K 9/107), flavone derivatives (A61K 31/352), and other therapeutic compositions targeting dermatological conditions (A61P 17/00, A61P 17/10) and musculoskeletal disorders (A61P 19/02). The patent designates 30+ European countries.

Pharmaceutical companies and manufacturers operating in the EU should review this publication for freedom-to-operate implications. Competitors developing similar formulations may need to design around this patent or evaluate licensing opportunities. Healthcare providers with R&D operations should monitor the prosecution of this application through to potential grant.

What to do next

  1. Monitor for updates
  2. Review for freedom-to-operate considerations

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

FORMULATION

Publication EP4034086A1 Kind: A1 Apr 08, 2026

Applicants

HEWLETT HEALTHCARE LIMITED

Inventors

COOPER, Nigel

IPC Classifications

A61K 9/107 20060101AFI20210402BHEP A61K 31/352 20060101ALI20210402BHEP A61K 31/465 20060101ALI20210402BHEP A61K 31/4741 20060101ALI20210402BHEP A61K 45/06 20060101ALI20210402BHEP A61P 17/00 20060101ALI20210402BHEP A61P 17/10 20060101ALI20210402BHEP A61P 19/02 20060101ALI20210402BHEP A61K 9/00 20060101ALI20210402BHEP A61K 47/10 20170101ALI20210402BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4034086A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Product Safety

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!